Metabolism and Disposition of Pacritinib (SB1518), an Orally Active Janus Kinase 2 Inhibitor in Preclinical Species and Humans

By  

Drug Metabolism Letters, Vol. 9, Iss. 1, 2015-04 ,pp. : 28-47

Bentham Science Publishers

Access to resources Recommend Favorite

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

By He Kan  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 36, Iss. 3, 2011-09 ,pp. : 129-139

Springer Publishing Company

Access to resources Recommend Favorite

Preclinical Drug Metabolism and Pharmacokinetics, and Prediction of Human Pharmacokinetics and Efficacious Dose of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237)

By  

Drug Metabolism Letters, Vol. 7, Iss. 2, 2014-05 ,pp. : 96-104

Bentham Science Publishers

Access to resources Recommend Favorite

Use of Pre-Clinical In Vitro and In Vivo Pharmacokinetics for the Selection of a Potent Hepatitis C Virus Protease Inhibitor, Boceprevir, for Clinical Development

By  

Letters in Drug Design & Discovery, Vol. 6, Iss. 4, 2009-06 ,pp. : 312-318

Bentham Science Publishers

Access to resources Recommend Favorite

Chemistry and Biology of Fascaplysin, a Potent Marine-Derived CDK-4 Inhibitor

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 7, 2012-06 ,pp. : 650-664

Bentham Science Publishers

Access to resources Recommend Favorite